People: Achillion Pharmaceuticals Inc (ACHN.O)
22 Sep 2017
Mr. David I. Scheer serves as Chairman of the Board of Achillion Pharmaceuticals, Inc., Since March 2010. Since 1981, Mr. Scheer has been President of Scheer & Company, Inc., which focuses on venture capital activities, corporate strategy, and transactional advisory services focused on life sciences. Mr. Scheer is on the Board of Directors, and also serves as Chairman of the Board, of Aegerion Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Scheer previously served on the Board of Directors of Tengion, Inc., a biopharmaceutical company. Mr. Scheer also serves as Chairman of the Board of two privately-held biotechnology companies. Additionally, Mr. Scheer serves on the Board of Directors of Connecticut United for Research Excellence, an educational and business advocacy network. He is on the Executive Board of the Center for Biomedical and Interventional Technologies (CBIT) at Yale University. He has been a co-organizer or Chair of a series of life science conferences involving public and global health in collaboration with Yale, and has been a speaker at the annual conferences involving orphan drug innovation for the National Organization for Rare Disorders. He serves as a member of a working group with the Division of Bioethics at NYU Langone Medical Center focusing on Expanded Access and Compassionate Use policy. Mr. Scheer has been invited to be a guest lecturer or panelist for courses at the Wharton School of the University of Pennsylvania, the Yale School of Management, and the University of New Haven, and has been an Executive-in-Residence at the Carey Business School at Johns Hopkins University. He has served as Chair of the Strategic Advisory Committee for the Global Task Force to Expand Access to Cancer Care in the Developing World, and as chair of the Unfinished Agenda in Infectious Diseases, both of which being initiatives associated with the Harvard School of Public Health. Mr. Scheer received an A.B. from Harvard College and a M.S. from Yale University.
|Total Annual Compensation,||--|
|Restricted Stock Awards,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|